Weighing Dose‐Related Benefits and Risks of Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
For patients with SLE, higher-dose HCQ improves effectiveness, with reduced risks of CAD and VTE. There was no dose-related difference in the risk of HCQ retinopathy for patients with SLE aged younger than 45 years. Our study emphasizes the need for weighing the benefits and risks of optimal HCQ dosage in managing SLE.
Authors
- Edward Chia‐Cheng Lai (ORCID: https://orcid.org/0000-0002-5852-7652)
- Brian Meng‐Hsun Li (ORCID: https://orcid.org/0009-0007-7445-8806)
- Meng‐Yu Weng (ORCID: https://orcid.org/0000-0002-0741-2134)
- Swu‐Jane Lin
- Jia‐Horung Hung
- Po‐Cheng Yang
Institutions
- University of Illinois Chicago (US)
- Vision Eye Institute (AU)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1002/art.70022
- Citations
- 1
- Primary Topic
- Drug-Induced Ocular Toxicity
- Type
- article
- Field-Weighted Citation Impact
- 1.71